2015
DOI: 10.7860/jcdr/2015/12958.6941
|View full text |Cite
|
Sign up to set email alerts
|

Clinical, Biochemical and Outcome Profile of Biotinidase Deficient Patients from Tertiary Centre in Northern India

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
8
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 16 publications
1
8
0
Order By: Relevance
“…Cutaneous manifestations including rash and alopecia were less commonly seen in our cohort (one of 10 and four of 10, respectively) consistent with previously published data on alopecia in Chinese patients [13]. In contrast, alopecia was found to be a common phenotype in Iranian and Indian patients (eight of 16 and nine of 10, respectively) [14,15]. Dermatological and neurological symptoms associated with the disease varied among the patients, and this could be due to the differences in the age of diagnosis and the age at biotin administration.…”
Section: Discussionsupporting
confidence: 91%
“…Cutaneous manifestations including rash and alopecia were less commonly seen in our cohort (one of 10 and four of 10, respectively) consistent with previously published data on alopecia in Chinese patients [13]. In contrast, alopecia was found to be a common phenotype in Iranian and Indian patients (eight of 16 and nine of 10, respectively) [14,15]. Dermatological and neurological symptoms associated with the disease varied among the patients, and this could be due to the differences in the age of diagnosis and the age at biotin administration.…”
Section: Discussionsupporting
confidence: 91%
“…Interestingly, cutaneous manifestations including skin eczema, alopecia, and recurrent fungal infection were less commonly seen compared with cases in the literature. In previous cohorts from Iran and India, alopecia was the common manifestation (8 of 16 and 9 of 10, respectively) [22, 23]. The first two patients had serum biotinidase activity < 10% of the control mean (classified as profound BTD), their mutations, c.460-1G > A/c.1382 T > C, though novel, must be severe.…”
Section: Discussionmentioning
confidence: 92%
“…6 Enzymatic activity (Profound < 10%, partial 10 -30%) determines the age of presentation and clinical spectrum. 7 Newborn screening (NBS) for BTD is an effective tool for early detection which is already adopted by various high prevalent counties like Israel. 8…”
Section: Discussionmentioning
confidence: 99%